Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Oct
12
Today In Oncology
Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress
Antidepressants May Improve Surgical Outcomes in Patients With GI Cancer and Depression
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Financial Toxicity Tied to Increased Risk of Mortality Among Patients With Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo